CytomX Therapeutics, Inc.

( )
CTMX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 4.54%75.040.0%$1283.83m
NVAXNovavax, Inc. 5.42%109.97251.8%$925.58m
VXRTVaxart, Inc. 40.02%16.970.0%$812.62m
AMGNAmgen, Inc. 1.22%253.091.3%$689.90m
REGNRegeneron Pharmaceuticals, Inc. 4.12%641.232.5%$651.41m
GILDGilead Sciences, Inc. 0.67%77.191.0%$624.99m
BIIBBiogen, Inc. 1.72%281.271.4%$586.19m
VRTXVertex Pharmaceuticals, Inc. 3.16%293.831.9%$476.84m
ILMNIllumina, Inc. 1.93%376.253.5%$300.68m
BNTXBioNTech SE 7.84%83.880.0%$230.63m
BMRNBioMarin Pharmaceutical, Inc. 1.63%126.434.3%$212.09m
ALXNAlexion Pharmaceuticals, Inc. 1.44%108.572.0%$207.18m
SGENSeattle Genetics, Inc. 2.88%173.436.1%$188.36m
SRNESorrento Therapeutics, Inc. 2.85%7.941.8%$185.99m
IMMUImmunomedics, Inc. 1.70%40.6511.0%$172.19m

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.